ArticleNature communications2021
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 67 citations in OpenAlex.
- Elesclomol-mediated cuproptosis overcomes cisplatin resistance by restricting epigenetically activated mitochondrial respiration: Novel therapeutic insights into cisplatin-elesclomol combination therapy.Acta pharmaceutica Sinica. B · 2026Article
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- IRF1 regulates apoptosis and osteogenic differentiation of bone marrow mesenchymal stem cells and ameliorates osteoporosis by activating the PI3K/AKT signaling pathway.Journal of advanced research · 2026Article
- Mitochondrial-endoplasmic reticulum interactions in lung diseases.Cell death & disease · 2026Review
- SMARCA4 deficiency contributes to platinum resistance in non-small cell lung cancer by activating the NF-κB-BIRC2/BIRC3 signaling axis.Journal of thoracic disease · 2026Article
- SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma.Nature communications · 2026Article
- SMARCA4 promotes lineage plasticity and enzalutamide resistance in prostate cancer by regulating PROX1 via H3K27 acetylation.Cell death discovery · 2026Article
- SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.NPJ precision oncology · 2026Article
- Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions.MedComm · 2026Review
- Small intestinal SMARCA4-deficient undifferentiated carcinoma with intussusception: A case report.Oncology letters · 2026Article
- Targeting mitochondrial homeostasis as a cancer treatment strategy: current status and future prospects.Molecular cancer · 2026Review
- The Role of Mitochondrial ROS in Neoplastic Transformations, Progression and Therapeutic Targeting.Oncology research · 2026Review
- Immunotherapy plus chemotherapy improves survival in SMARCA4-deficient NSCLC: a real-world cohort study.Frontiers in immunology · 2026Article
- FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.Cancers · 2025Review
- Identification and experimental validation of biomarkers associated with paraptosis in meningioma.Medicine · 2025Article
- MPTP mediated Ox-mtDNA release inducing macrophage pyroptosis and exacerbating MCD-induced MASH via promoting the ITPR3/CaJournal of translational medicine · 2025Article
- Targeting metalloptosis in tumor therapy: from molecular mechanisms to application of metal nanoparticles.Molecular cancer · 2025Review
- Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC.Nature communications · 2025Article
- TRPM2-mediated feed-forward loop promotes chondrocyte damage in osteoarthritis via calcium-cGAS-STING-NF-κB pathway.Journal of advanced research · 2025Article
- Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis.The oncologist · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
29 authors at 6 institutions in 2 countries.
Yibo Xue *Department of Biochemistry, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0003-4252-4446
Jordan L Morris *Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-4663-4776
Kangning Yang *Department of Biochemistry, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-5211-913X
Zheng FuDepartment of Biochemistry, McGill University, Montreal, QC, Canada.
Xianbing ZhuDepartment of Biochemistry, McGill University, Montreal, QC, Canada.
Fraser JohnsonDepartment of Integrative Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
Brian MeehanDepartment of Pediatrics, Research Institute of the McGill University Health Centre, Montreal Children's Hospital, McGill University, Montreal, QC, Canada.
Leora WitkowskiDepartment of Human Genetics, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-5736-2534
Amber YasmeenDivision of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Tunde GolenarDepartment of Biochemistry, McGill University, Montreal, QC, Canada.
Mackenzie CoathamDepartment of Oncology, Department of Obstetrics and Gynecology, University of Alberta, Edmonton, AB, Canada.
Geneviève MorinDepartment of Biochemistry, McGill University, Montreal, QC, Canada.
Anie MonastDepartment of Biochemistry, McGill University, Montreal, QC, Canada.
Virginie PilonDepartment of Biochemistry, McGill University, Montreal, QC, Canada.
Pierre Olivier FisetDepartment of Pathology, McGill University Health Centre, Montreal, QC, Canada.
Sungmi JungDepartment of Pathology, McGill University Health Centre, Montreal, QC, Canada.
Anne V GonzalezDepartment of Medicine, Division of Respiratory Medicine, McGill University Health Centre, Montreal Chest Institute, Montreal, QC, Canada.
Sophie Camilleri-BroetDepartment of Pathology, McGill University Health Centre, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-3453-636X
Lili FuDepartment of Pathology, McGill University Health Centre, Montreal, QC, Canada.
Lynne-Marie PostovitDepartment of Oncology, Department of Obstetrics and Gynecology, University of Alberta, Edmonton, AB, Canada.
Jonathan SpicerDepartment of Surgery, McGill University Health Center, Montreal, QC, Canada.ORCID http://orcid.org/0000-0003-2708-1309
Walter H GotliebDivision of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Marie-Christine GuiotDepartment of Pathology, Montreal Neurological Hospital/Institute, McGill University Health Centre, Montreal, QC, Canada.
Janusz RakDepartment of Pediatrics, Research Institute of the McGill University Health Centre, Montreal Children's Hospital, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-2912-5566
Morag ParkDepartment of Biochemistry, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-5400-606X
William LockwoodDepartment of Integrative Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-9831-3408
William D FoulkesDepartment of Human Genetics, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-7427-4651
Julien PrudentMedical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK. julien.prudent@mrc-mbu.cam.ac.uk.ORCID http://orcid.org/0000-0003-3821-6088
Sidong HuangDepartment of Biochemistry, McGill University, Montreal, QC, Canada. sidong.huang@mcgill.ca.ORCID http://orcid.org/0000-0002-2838-4726
McGill University Health Centre · CAJewish General Hospital · CABC Cancer Agency · CAMontreal Children's Hospital · CAUniversity of Alberta · CAUniversity of Cambridge · GB
Funding
CIHR FDN-148390CIHR MFE-171249CIHR MOP-130540CIHR PJT-156233CIHR PJT-438303Medical Research Council MC_UU_00015/7
Abstract
Inactivating mutations in SMARCA4 and concurrent epigenetic silencing of SMARCA2 characterize subsets of ovarian and lung cancers. Concomitant loss of these key subunits of SWI/SNF chromatin remodeling complexes in both cancers is associated with chemotherapy resistance and poor prognosis. Here, we discover that SMARCA4/2 loss inhibits chemotherapy-induced apoptosis through disrupting intracellular organelle calcium ion (Ca
Indexed as
MutationAnimalsAntineoplastic AgentsApoptosisCalciumCell Line, TumorDNA HelicasesGene Expression ProfilingGene Expression Regulation, NeoplasticHEK293 CellsHumansInositol 1,4,5-Trisphosphate ReceptorsIon TransportMaleMiceMice, Inbred NODAntineoplastic AgentsCalciumDNA HelicasesInositol 1,4,5-Trisphosphate ReceptorsITPR3 protein, humanNuclear ProteinsSMARCA2 protein, humanSMARCA4 protein, humanTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.